• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

急性髓系白血病异基因造血细胞移植的预处理方案:来自日本登记研究的真实世界数据。

Conditioning regimens for allogeneic hematopoietic cell transplantation in acute myeloid leukemia: Real-world data from the Japanese registry studies.

作者信息

Yanada Masamitsu, Harada Kaito, Shimomura Yoshimitsu, Arai Yasuyuki, Konuma Takaaki

机构信息

Department of Hematology and Cell Therapy, Aichi Cancer Center, Nagoya, Japan.

Department of Hematology and Oncology, Tokai University School of Medicine, Isehara, Japan.

出版信息

Front Oncol. 2022 Nov 25;12:1050633. doi: 10.3389/fonc.2022.1050633. eCollection 2022.

DOI:10.3389/fonc.2022.1050633
PMID:36505853
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9732425/
Abstract

Conditioning regimens play a crucial role in preventing relapse of acute myeloid leukemia (AML) following allogeneic hematopoietic cell transplantation (HCT). In early times, myeloablative conditioning was used exclusively, but it was associated with significant toxicity. However, the advent of reduced-intensity conditioning has allowed allogeneic HCT to be performed more safely, leading to an expansion of our choices for conditioning regimens. As the transplantation methods have become highly diversified, it is reasonable to determine an optimal conditioning regimen in consideration of patient-, disease-, and transplantation-related factors. In this context, large-scale registry-based studies provide real-world data to allow for a detailed evaluation of the utility of individual conditioning regimens in specific clinical settings. The Japanese Society for Transplantation and Cellular Therapy has been conducting a nationwide survey for HCT since 1993 that currently covers >99% of all the transplantation centers nationwide, and >1,000 allogeneic HCTs performed for adults with AML are registered per year. We have been using the registry data to implement a number of studies focusing on adults with AML, and the large number of patients registered consecutively from nearly all transplantation centers nationwide represent real-world practice in Japan. This article reviews and discusses the results obtained from our registry-based studies pertaining to various conditioning regimens.

摘要

预处理方案在异基因造血细胞移植(HCT)后预防急性髓系白血病(AML)复发中起着关键作用。早期,仅使用清髓性预处理,但它与显著的毒性相关。然而,减低强度预处理的出现使异基因HCT能够更安全地进行,从而扩大了我们对预处理方案的选择范围。随着移植方法变得高度多样化,考虑患者、疾病和移植相关因素来确定最佳预处理方案是合理的。在此背景下,基于登记处的大规模研究提供了真实世界的数据,以便在特定临床环境中详细评估各个预处理方案的效用。日本移植与细胞治疗学会自1993年以来一直在全国范围内对HCT进行调查,目前覆盖全国所有移植中心的99%以上,每年有超过1000例为成年AML患者进行的异基因HCT登记。我们一直在使用登记数据开展多项针对成年AML患者的研究,几乎来自全国所有移植中心连续登记的大量患者代表了日本的真实世界实践。本文回顾并讨论了我们基于登记处的研究中关于各种预处理方案所获得的结果。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8c48/9732425/2a7e2517a7b6/fonc-12-1050633-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8c48/9732425/2a7e2517a7b6/fonc-12-1050633-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8c48/9732425/2a7e2517a7b6/fonc-12-1050633-g001.jpg

相似文献

1
Conditioning regimens for allogeneic hematopoietic cell transplantation in acute myeloid leukemia: Real-world data from the Japanese registry studies.急性髓系白血病异基因造血细胞移植的预处理方案:来自日本登记研究的真实世界数据。
Front Oncol. 2022 Nov 25;12:1050633. doi: 10.3389/fonc.2022.1050633. eCollection 2022.
2
Comparison of Outcomes for Pediatric Patients With Acute Myeloid Leukemia in Remission and Undergoing Allogeneic Hematopoietic Cell Transplantation With Myeloablative Conditioning Regimens Based on Either Intravenous Busulfan or Total Body Irradiation: A Report From the Japanese Society for Hematopoietic Cell Transplantation.基于静脉注射白消安或全身照射的清髓性预处理方案对急性髓系白血病缓解期并接受异基因造血细胞移植的儿科患者的结局比较:来自日本造血细胞移植学会的报告
Biol Blood Marrow Transplant. 2015 Dec;21(12):2141-2147. doi: 10.1016/j.bbmt.2015.08.011. Epub 2015 Aug 10.
3
Hematopoietic cell transplantation in adults with acute myeloid leukemia: A review of the results from various nationwide registry studies in Japan.日本成人急性髓系白血病造血细胞移植:对各项全国性登记研究结果的综述
Blood Cell Ther. 2021 Apr 2;4(2):35-43. doi: 10.31547/bct-2020-023. eCollection 2021 May 25.
4
Comparison of reduced-intensity and myeloablative conditioning regimens for allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia and acute lymphoblastic leukemia: a meta-analysis.急性髓系白血病和急性淋巴细胞白血病患者异基因造血干细胞移植中减低强度与清髓性预处理方案的比较:一项荟萃分析
Stem Cells Dev. 2014 Nov 1;23(21):2535-52. doi: 10.1089/scd.2014.0123. Epub 2014 Sep 17.
5
Measurable residual disease, conditioning regimen intensity, and age predict outcome of allogeneic hematopoietic cell transplantation for acute myeloid leukemia in first remission: A registry analysis of 2292 patients by the Acute Leukemia Working Party European Society of Blood and Marrow Transplantation.可测量残留疾病、调理方案强度和年龄可预测首次缓解的急性髓系白血病患者接受异基因造血细胞移植的结果:欧洲血液和骨髓移植学会急性白血病工作组对 2292 例患者的注册分析。
Am J Hematol. 2018 Sep;93(9):1142-1152. doi: 10.1002/ajh.25211. Epub 2018 Aug 15.
6
Reducing Mortality of Single-Unit Unrelated Cord Blood Transplantation for Relapsed Acute Myeloid Leukemia after a Previous Allogeneic Transplantation: A Real-World Retrospective Study Over the Past 19 Years in Japan.在日本,过去 19 年的真实世界回顾性研究表明,降低异基因移植后复发的急性髓系白血病患者行单份无关脐带血移植的死亡率。
Transplant Cell Ther. 2022 Nov;28(11):777.e1-777.e11. doi: 10.1016/j.jtct.2022.08.006. Epub 2022 Aug 12.
7
Long-term outcome after a treosulfan-based conditioning regimen for patients with acute myeloid leukemia: A report from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.基于苏消安预处理方案治疗急性髓系白血病患者的长期预后:欧洲血液与骨髓移植学会急性白血病工作组的报告
Cancer. 2017 Jul 15;123(14):2671-2679. doi: 10.1002/cncr.30646. Epub 2017 Mar 22.
8
Allogeneic hematopoietic cell transplantation for adults with acute myeloid leukemia conducted in Japan during the past quarter century.过去四分之一个世纪在日本进行的成人急性髓系白血病异基因造血细胞移植。
Ann Hematol. 2020 Jun;99(6):1351-1360. doi: 10.1007/s00277-020-04051-0. Epub 2020 May 4.
9
Conditioning Intensity for Allogeneic Hematopoietic Cell Transplantation in Acute Myeloid Leukemia Patients with Poor-Prognosis Cytogenetics in First Complete Remission.在首次完全缓解的伴有不良预后细胞遗传学的急性髓系白血病患者中进行异基因造血细胞移植的预处理强度。
Biol Blood Marrow Transplant. 2020 Mar;26(3):463-471. doi: 10.1016/j.bbmt.2019.09.025. Epub 2019 Sep 25.
10
Reduced-intensity conditioning allogeneic hematopoietic cell transplantation in adults with acute myeloid leukemia.成人急性髓系白血病的低强度预处理异基因造血细胞移植。
Cancer Control. 2011 Oct;18(4):237-45. doi: 10.1177/107327481101800404.

引用本文的文献

1
Different impacts of granulocyte colony-stimulating factor administration on allogeneic hematopoietic cell transplant outcomes for adult acute myeloid leukemia according to graft type.根据移植物类型,粒细胞集落刺激因子给药对成人急性髓系白血病异基因造血细胞移植结局的不同影响。
Am J Hematol. 2025 Jan;100(1):66-77. doi: 10.1002/ajh.27521. Epub 2024 Nov 20.
2
Age and dose dependent changes to the bone and bone marrow microenvironment after cytotoxic conditioning with busulfan.白消安细胞毒性预处理后,骨骼和骨髓微环境随年龄和剂量的依赖性变化。
Front Cell Dev Biol. 2024 Jul 30;12:1441381. doi: 10.3389/fcell.2024.1441381. eCollection 2024.
3

本文引用的文献

1
Hematopoietic cell transplantation in adults with acute myeloid leukemia: A review of the results from various nationwide registry studies in Japan.日本成人急性髓系白血病造血细胞移植:对各项全国性登记研究结果的综述
Blood Cell Ther. 2021 Apr 2;4(2):35-43. doi: 10.31547/bct-2020-023. eCollection 2021 May 25.
2
Favorable Outcome with Conditioning Regimen of Flu/Bu4/Mel in Acute Myeloid Leukemia Patients in Remission Undergoing Cord Blood Transplantation.氟达拉滨/白消安/米托蒽醌预处理方案在缓解期行脐血移植的急性髓系白血病患者中的疗效良好。
Transplant Cell Ther. 2022 Nov;28(11):775.e1-775.e9. doi: 10.1016/j.jtct.2022.07.026. Epub 2022 Aug 1.
3
Allogeneic Stem Cell Transplantation in Refractory Acute Myeloid Leukaemia.
异体造血干细胞移植治疗难治性急性髓系白血病。
Cells. 2024 Apr 26;13(9):755. doi: 10.3390/cells13090755.
4
Reduced toxicity (FluBu3) versus myeloablative (BuCy) conditioning in acute myeloid leukemia patients who received first allogeneic hematopoietic stem cell transplantation in measurable residual disease-negative CR1.在无微小残留病灶完全缓解 1 期的急性髓系白血病患者中,接受首次异基因造血干细胞移植时,与清髓性(BuCy)预处理相比,毒性降低(FluBu3)。
Bone Marrow Transplant. 2024 Jun;59(6):813-823. doi: 10.1038/s41409-024-02255-w. Epub 2024 Mar 4.
5
The effect of center experience on allogeneic hematopoietic cell transplantation outcomes in acute myeloid leukemia.中心经验对急性髓细胞白血病异基因造血细胞移植结局的影响。
Bone Marrow Transplant. 2024 Apr;59(4):541-549. doi: 10.1038/s41409-024-02222-5. Epub 2024 Feb 6.
6
External validation and extended application of the transplant conditioning intensity score in acute myeloid leukemia.移植预处理强度评分在急性髓系白血病中的外部验证及扩展应用
Bone Marrow Transplant. 2023 Oct;58(10):1096-1103. doi: 10.1038/s41409-023-02037-w. Epub 2023 Jul 13.
Improved trends in survival and engraftment after single cord blood transplantation for adult acute myeloid leukemia.
成人急性髓系白血病患者行单份脐带血移植后生存和植入情况的改善趋势。
Blood Cancer J. 2022 May 25;12(5):81. doi: 10.1038/s41408-022-00678-6.
4
Prognostic value of measurable residual disease at allogeneic transplantation for adults with core binding factor acute myeloid leukemia in complete remission.完全缓解的成人核心结合因子急性髓系白血病患者异基因移植时可测量残留病的预后价值
Bone Marrow Transplant. 2021 Nov;56(11):2779-2787. doi: 10.1038/s41409-021-01409-4. Epub 2021 Jul 16.
5
Comparison of fludarabine, a myeloablative dose of busulfan, and melphalan vs conventional myeloablative conditioning regimen in patients with relapse and refractory acute myeloid leukemia in non-remission status.氟达拉滨、大剂量白消安和马法兰与传统清髓性预处理方案在复发及难治性非缓解状态急性髓系白血病患者中的比较。
Bone Marrow Transplant. 2021 Sep;56(9):2302-2304. doi: 10.1038/s41409-021-01380-0. Epub 2021 Jun 21.
6
Prognostic Impact of the Fractionation of Total Body Irradiation for Patients with Acute Myeloid Leukemia Undergoing Myeloablative Allogeneic Hematopoietic Cell Transplantation.全身照射分割对行清髓性异基因造血细胞移植的急性髓系白血病患者预后的影响。
Transplant Cell Ther. 2021 Feb;27(2):185.e1-185.e6. doi: 10.1016/j.jtct.2020.10.018. Epub 2020 Dec 13.
7
The evolving concept of indications for allogeneic hematopoietic cell transplantation during first complete remission of acute myeloid leukemia.急性髓系白血病首次完全缓解期间异基因造血细胞移植适应证的不断演变。
Bone Marrow Transplant. 2021 Jun;56(6):1257-1265. doi: 10.1038/s41409-021-01247-4. Epub 2021 Mar 8.
8
Adding melphalan to fludarabine and a myeloablative dose of busulfan improved survival after allogeneic hematopoietic stem cell transplantation in a propensity score-matched cohort of hematological malignancies.在血液恶性肿瘤患者的倾向评分匹配队列中,与氟达拉滨和大剂量白消安相比,添加美法仑可改善异基因造血干细胞移植后的生存。
Bone Marrow Transplant. 2021 Jul;56(7):1691-1699. doi: 10.1038/s41409-021-01217-w. Epub 2021 Mar 3.
9
Does one model fit all? Predicting non-relapse mortality after allogeneic hematopoietic cell transplantation.一种模型适用于所有情况吗?预测异基因造血细胞移植后的非复发死亡率。
Bone Marrow Transplant. 2021 Jul;56(7):1720-1722. doi: 10.1038/s41409-021-01236-7. Epub 2021 Mar 3.
10
Augmented Reduced-Intensity Regimen Does Not Improve Postallogeneic Transplant Outcomes in Acute Myeloid Leukemia.增强的减低强度方案并不能改善急性髓系白血病患者异基因移植后的结局。
J Clin Oncol. 2021 Mar 1;39(7):768-778. doi: 10.1200/JCO.20.02308. Epub 2020 Dec 29.